Barranco Gilberto, Fernández Edith, Rivas Silvia, Quezada Roxana, Nava Dolores, Aguilar José, García Abelardo, Astudillo Horacio, Lome Carmen, Ruiz Erika
Department of Hematology, General Hospital of Mexico, Mexico City.
Translational Medicine, National Institute of Cancerology, Mexico City.
Hematol Rep. 2019 Sep 18;11(3):7964. doi: 10.4081/hr.2019.7964.
The aim of this study is to explore the expression of osteopontin (OPN) and its relationship with prognostic factors and survival in diffuse large B cell lymphoma (DLBCL). A tissue microarray was performed for immunohistochemical evaluation. Contingency tables were analyzed for trends; chi-square test was used to determine differences between groups. Univariate and multivariate Cox proportional hazards-regression analyses were performed to evaluate the impact of prognostic factors on survival. Expression of OPN was observed in 28%. It was different in non-germinal center DLBCL (P=0.04). The mean overall survival (OS) was lower in patients with positive OPN expression (19.762; CI 95% 14.269-25.255) it was not significant (P=0.123). It is not possible to establish a clear relationship between the expression by immunohistochemistry of osteopontin and a poor prognosis but it would be important to complement the analysis with other techniques as PCR or NGS that allow us to assess the influence of the isoforms and post-translational modifications of OPN on the biological behavior of DLBCL. Our findings indicate that OPN expression could be associated with a more aggressive variant of lymphoma: non-germinal center DLBCL.
本研究旨在探讨骨桥蛋白（OPN）在弥漫性大B细胞淋巴瘤（DLBCL）中的表达及其与预后因素和生存的关系。进行组织芯片免疫组化评估。分析列联表的趋势；采用卡方检验确定组间差异。进行单因素和多因素Cox比例风险回归分析，以评估预后因素对生存的影响。观察到28%的病例中有OPN表达。在非生发中心DLBCL中其表达不同（P=0.04）。OPN表达阳性患者的平均总生存期（OS）较低（19.762；95%置信区间14.269 - 25.255），但差异无统计学意义（P=0.123）。通过免疫组化检测的骨桥蛋白表达与不良预后之间无法建立明确的关系，但用其他技术如PCR或NGS来补充分析很重要，这些技术能让我们评估OPN的异构体和翻译后修饰对DLBCL生物学行为的影响。我们的研究结果表明，OPN表达可能与一种侵袭性更强的淋巴瘤变体有关：非生发中心DLBCL。
